The Southern Consortium Node (SCN) has been an integral part of the NIDA-funded Clinical Trials Network (CTN) consortium since 2000, evolving to meet changing CTN needs and leading and contributing to a portfolio of compelling addiction science and treatment research projects with outstanding performance metrics. We have expanded our network throughout the Southeast and established close and collaborative working relationships with a diverse and geographically dispersed group of programs including primary care and medical specialty practices. We have a cost-effective system for accessing specialized expertise for specific CTN trials. We have solid collaborative relationships with community substance use disorder (SUD) treatment programs, primary care providers and governmental agencies that facilitate research, implementation and dissemination efforts. Our CTN efforts are complemented and enhanced by our statewide CTSA infrastructure, creating a research capacity that extends far beyond our academic home. For this renewal, we propose to further expand our network to include six rural states in the Southeast with a research agenda focused on best practices for bringing evidence-based care to underserved rural populations across the full continuum of care. We will develop a Health Technology Core to facilitate exploration of the use of technology to address health disparities in SUD treatment. We will develop an Implementation Science Core and employ Learning Health System principles to move positive findings into our partnering practice systems, fulfilling the core CTN mission of moving evidence-based treatment beyond academic settings. In sum, the SCN has demonstrated remarkable flexibility, creativity and the collaborative and innovative spirit required to meet new challenges and take advantage of growing CTN opportunities. We have gathered a multidisciplinary team with expertise in addiction psychiatry, clinical research, informatics, analytics, healthcare technology, dissemination and implementation science. We will employ our resources and expertise in innovative areas to address identified gaps in access, engagement and retention in treatment for individuals with SUDs. The SCN team looks forward to continued participation in the CTN consortium.

Public Health Relevance

The Clinical Trials Network (CTN) is a cooperative agreement between NIDA, treatment providers, and researchers throughout the nation in which science is being utilized as a vehicle to improve the treatment of substance use disorders. It is the goal of the Southern Consortium Node (SCN) to work collaboratively with the CCTN, the NIDA-contracted coordinating and data centers, and other CTN Nodes in conducting and directing multi-site clinical trials, implementation and dissemination efforts.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
3UG1DA013727-21S1
Application #
10163408
Study Section
Special Emphasis Panel (ZDA1)
Program Officer
Dobbins, Ronald
Project Start
2000-09-30
Project End
2025-02-28
Budget Start
2020-06-01
Budget End
2021-02-28
Support Year
21
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Medical University of South Carolina
Department
Psychiatry
Type
Schools of Medicine
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29407
Baker, Nathaniel L; Gray, Kevin M; Sherman, Brian J et al. (2018) Biological correlates of self-reported new and continued abstinence in cannabis cessation treatment clinical trials. Drug Alcohol Depend 187:270-277
Garrett, Sharon B; Doyle, Suzanne R; Peavy, K Michelle et al. (2018) Age differences in outcomes among patients in the ""Stimulant Abuser Groups to Engage in 12-Step"" (STAGE-12) intervention. J Subst Abuse Treat 84:21-29
Tomko, Rachel L; Baker, Nathaniel L; McClure, Erin A et al. (2018) Incremental validity of estimated cannabis grams as a predictor of problems and cannabinoid biomarkers: Evidence from a clinical trial. Drug Alcohol Depend 182:1-7
Squeglia, Lindsay M; Tomko, Rachel L; Baker, Nathaniel L et al. (2018) The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial. Drug Alcohol Depend 185:17-22
Winhusen, Theresa; Feaster, Daniel J; Duan, Rui et al. (2018) Baseline Cigarette Smoking Status as a Predictor of Virologic Suppression and CD4 Cell Count During One-Year Follow-Up in Substance Users with Uncontrolled HIV Infection. AIDS Behav 22:2026-2032
Tomko, Rachel L; Jones, Jennifer L; Gilmore, Amanda K et al. (2018) N-acetylcysteine: A potential treatment for substance use disorders. Curr Psychiatr 17:30-36, 41-42, 55
McClure, Erin A; Baker, Nathaniel L; Sonne, Susan C et al. (2018) Tobacco use during cannabis cessation: Use patterns and impact on abstinence in a National Drug Abuse Treatment Clinical Trials Network study. Drug Alcohol Depend 192:59-66
Trivedi, Madhukar H; Greer, Tracy L; Rethorst, Chad D et al. (2017) Randomized Controlled Trial Comparing Exercise to Health Education for Stimulant Use Disorder: Results From the CTN-0037 STimulant Reduction Intervention Using Dosed Exercise (STRIDE) Study. J Clin Psychiatry 78:1075-1082
Montgomery, LaTrice; Burlew, A Kathleen; Korte, Jeffrey E (2017) Does change in readiness influence retention among African American women and men in substance abuse treatment? J Ethn Subst Abuse 16:420-431
McClure, Erin A; King, Jacqueline S; Wahle, Aimee et al. (2017) Comparing adult cannabis treatment-seekers enrolled in a clinical trial with national samples of cannabis users in the United States. Drug Alcohol Depend 176:14-20

Showing the most recent 10 out of 33 publications